Degenerative-involutional brain psychoorganichni syndromes or secondary consequences of cerebrovascular insufficiency, that is, primary and secondary disorders of mental activity in the elderly, characterized by memory impairment, confusion, disorientation, reduced motivation and initiative, reduced ability to concentrate; changes in the emotional and behavioral sphere: emotional instability, irritability, indifference to the environment; pseudomelanholia in the elderly.
active substance: choline alfoscerate;
1 capsule contains choline alfoscerate 400 mg;
excipients: glycerin, purified water;
components of the capsule shell: gelatin, esitol, sorbitol sodium solution methyl parahydroxybenzoate (E 215), sodium propyl parahydroxybenzoate (E 217), titanium dioxide (E 171), iron oxide (E 172).
Gliatilin Dosage form
Basic physical and chemical properties: oval, yellow, soft opaque gelatin capsules containing a viscous solution.
Gliatilin Pharmacotherapeutic group
Drugs affecting the nervous system. Parasympathomimetics. Choline alfoscerate. ATX code N07A X02.
Gliatilin is a drug that belongs to the group of central cholinomimetics with a predominant effect on the central nervous system (CNS). Choline alfoscerate as a carrier of choline and a previous agent of phosphatidylcholine has the potential ability to prevent and correct biochemical damage, which is of particular importance among the pathogenic factors of psychoorganic involutional syndrome, that is, it can affect a decreased cholinergic tone and altered the phospholipid composition of the membranes of nerve cells. The drug contains 40.5% of metabolically protected choline. Metabolic protection is provided by the release of choline in the brain. Gliatilin has a positive effect on memory functions and cognitive abilities, as well as on indicators of emotional state and behavior, the deterioration of which was caused by the development of involutional brain pathology.
The mechanism of action is based on the fact that when choline enters the body, alfoscerate is split under the action of enzymes into choline and glycerophosphate: choline takes part in the biosynthesis of acetylcholine – one of the main mediators of nervous excitement; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) of the neuronal membrane. Thus, Gliatilin improves the transmission of nerve impulses in cholinergic neurons; positively affects the plasticity of neuronal membranes and receptor function. Gliatilin improves cerebral blood flow, enhances metabolic processes in the brain, activates the structures of the reticular formation of the brain and restores consciousness in traumatic brain damage.
On average, about 88% of the administered dose of Gliatilin is absorbed. The drug accumulates mainly in the brain (45% of the drug concentration in the blood), lungs and liver. Elimination of the drug occurs mainly through the lungs in the form of carbon dioxide (CO2). Only 15% is excreted in urine and bile.
Degenerative-involutional brain psychoorganic syndromes or secondary consequences of cerebrovascular insufficiency, that is, primary and secondary disorders of mental activity in the elderly, which are characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, decreased ability to concentrate; changes in the emotional and behavioral sphere: emotional instability, irritability, indifference to the environment; pseudomelancholia in the elderly.
Hypersensitivity to the components of the drug.
Psychotic syndrome, severe psychomotor agitation.
During pregnancy and breastfeeding.
Interaction with other medicinal products and other types of interactions
Clinically significant interaction of the drug with other drugs has not been established.
If you have a history of intolerance to some sugars, consult your doctor before taking this medication.